Posted by Michael Wonder on 13 Dec 2019
Novartis completes certification of initial sites in Ontario for first approved Canadian CAR-T therapy, Kymriah (tisagenlecleucel)
12 December 2019 - Ontario government to reimburse Kymriah therapy for certain patients with life-threatening cancers who are in critical need.
Novartis Pharmaceuticals Canada is pleased to announce that sites in Ontario have been certified in accordance with applicable requirements to treat eligible patients with Kymriah (tisagenlecleucel), the first chimeric antigen receptor T cell (CAR-T) therapy that received regulatory approval in Canada.
Patients with relapsed/refractory (r/r) paediatric and young adult B-cell acute lymphoblastic leukaemia and adult r/r diffuse large B-cell lymphoma may be eligible to be treated with Kymriah at one of the initially certified Canadian treatment sites.
